On May 28, 2021, the U.S. Department of Defense (DOD), on behalf of and in coordination with the U.S. Department of Health and Human Services (HHS), awarded a $4.6 million contract to DiaSorin Inc. to increase production capacity of LIAISON SARS-CoV-2 TrimericS IgG serology tests to support the domestic COVID-19 response.
The LIAISON SARS-CoV-2 TrimericS IgG antibody test joins the LIAISON SARS-CoV-2 Ag antigen test in the COVID testing portfolio developed by DiaSorin. This industrial base expansion effort will allow DiaSorin Inc. to increase its production capacity of LIAISON SARS-CoV-2 TrimericS IgG tests in its Stillwater, Minnesota, facility from 1.3 million tests per month to 10 million per month by May 2022.
The DOD’s Defense Assisted Acquisition (DA2) Cell led this effort in coordination with the Department of the Air Force’s Acquisition COVID-19 Task Force (DAF ACT). The Biomedical Advanced Research and Development Authority (BARDA), within HHS the Office of the Assistant Secretary for Preparedness and Response, funded this effort through the Health Care Enhancement Act (HCEA) to support domestic industrial base expansion for critical medical resources.
This award is one component of BARDA’s expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
About DiaSorin Inc.:
DiaSorin is a global leader in the laboratory diagnostics market, specializing in the immunodiagnostics and molecular diagnostics segments. For over 50 years DiaSorin Group has been developing, producing, and commercializing diagnostic tests. DiaSorin supports clinical laboratory needs and activities, providing solutions that are reliable, innovative, fully automated and standardized. DiaSorin continually invests in Research & Development, using distinctive expertise in the field to deliver a high level of innovation. More information is available at: https://www.diasorin.com.